Avodart, Real World Data

Gary Ong, General Manager, Global Dermatology Medical, GSK

3-Year Long-Term Data Disclosure

Better and safer than Finasteride

GSK's large-scale real-world clinical results of Avodart, a treatment for prostatic hypertrophy, which marks the 13th anniversary of its launch in Korea, have been released for the first time.

 

Based on actual field data, the company expressed its ambition to further strengthen Avodart's position in early hair loss treatment.LEAD clinical trials are the first RealWorld study conducted to evaluate the long-term clinical usefulness of Avodart in Korean male hair loss patients.

 

It was compared with Finasteride, the two major mountain ranges for oral hair loss treatment.

 

600 patients participated in five general hospitals in Korea, including Inha University Hospital and Gangdong Kyung Hee University Hospital, and the average analysis period reached 3.4 years.

 

In particular, the Korean Hair Loss Type Classification Act (BASP) developed by the Hair Institute for data analysis with the domestic medical staff was applied.

 

The accuracy of the evaluation was improved by using the Korean classification method, not the Western classification method, which is difficult to apply to Koreans.

 

Dr.

 

Gary Ong, general manager of GSK Global Dermatology Medical, who led the LEAD clinical trial, said, "This study confirmed that Avodart is more effective in treating male hair loss based on Korean classification," adding, "M-shaped hair loss is the part that patients care the most, and Avodart showed good results compared to Finasteride." LEAD clinical results showed that Avodart had a significantly higher cumulative number of patients with improved symptoms compared to Finasteride in most types of hair loss.

 

In M-shaped hair loss, which is most common in Korean men, the proportion of patients with improved symptoms was 86.0% for Avodart and 45.5% for Finasteride, showing a difference of more than 40%p.

 

The improvement rate of hair growth was also about twice as high in the Avodart group as in the Finasteride group.

 

A common misconception about Avodart is that it has higher side effects than Finasteride, which inhibits only type 2 by inhibiting both type 1 and type 2 of 5-alpha reductase.

 

As a result of the Real World study, Avodart showed only a similar level of adverse reactions to Finasteride.

 

Dr.

 

Gary Ong said, "As a result, Avodart was more effective, and safety was similar.

 

"I think the results of this study not only help reduce misunderstandings and prejudices about Avodart but also help doctors make more appropriate decisions when prescribing it in real life," he explained.

 

Based on the results of the first Real World, GSK set a goal of further enhancing Avodart's position as a primary treatment in the Korean hair loss market.

 

This is because there is still a high perception that finasteride is used first in the early stages of hair loss and Avodart is used after further progress.

 

Dr.

 

Gary Ong said, "This study broadens the path to prescribing Avodart as a primary treatment.

 

Male-type hair loss is a progressive disease, so you need to start treatment as soon as possible to get better results in the long term, he stressed.

 

In order to achieve this goal, GSK Korea has recently increased its marketing staff.

 

BM Kim Hwan-geun, who joined Avodart marketing two months ago, said, "Avodart has maintained the top prescription for oral male hair loss treatment from the fourth quarter of 2020 to the second quarter of 2022, and real-world data for 600 Koreans will have a positive impact on Avodart's prescription expansion." "Avodart started as a latecomer amid fierce competition and showed double-digit growth every year," said BM, in charge of Avodart.

 

As it is expected to grow further in the future, two managers will join us in marketing, he said.

 

"We will try to make Avodart the epitome of hair loss treatments next year."